Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426)

discusses the updated data with a minimum of 23 months’ follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds.

Related Episodes

Episode 135: The STAR Study
Episode 122: The Uromigos Legends in GU Cancer series – Nick Vogelzang: renal cancer
Episode 117: PD1/VEGF adverse event management in renal cancer
Episode 116: Renal cancer surgery controversies at EAU
Episode 111: The randomised phase 3 CANTATA in metastatic renal cancer
Episode 109: Adjuvant pembrolizumab in renal cancer
Episode 103: Targeting the microbiome increases the activity of immune therapy in renal cancer
Episode 102: Adjuvant therapy in melanoma – how it will help inform the renal community
Episode 101: The Uromigos Paper of the Month – Belzutifan in renal cancer
Episode 99: Navigating social media from a patients’ perspective